Literature DB >> 6514833

Effects of naloxone and buprenorphine on intravenous acetaldehyde self-injection in rats.

W D Myers, K T Ng, G Singer.   

Abstract

Rats can be induced to self-inject acetaldehyde under an appropriate operant conditioning schedule. The narcotic antagonist naloxone (30 mg/kg) is shown to produce a decrease in schedule-induced acetaldehyde self-injection, but was without effect on both barpress responding and spontaneous activity in rats tested individually for fine, gross and total activity. On the other hand buprenorphine (0.3 and 3 mg/kg), the mixed agonist-antagonist derived from the opium alkaloid thebaine, also produced a significant decrease in acetaldehyde self-injection. However, a significant effect of buprenorphine on barpressing in otherwise drug naive rats indicated that this finding should not be dissociated from a possible involvement of buprenorphine on motor responding. While the findings are consistent with the hypothesis of opiate involvement in acetaldehyde self-administration, caution must be exercised when drawing conclusions about the participation of endogenous opiates in acetaldehyde-mediated behavior.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6514833     DOI: 10.1016/0031-9384(84)90168-9

Source DB:  PubMed          Journal:  Physiol Behav        ISSN: 0031-9384


  10 in total

Review 1.  Behavioral mechanisms underlying nicotine reinforcement.

Authors:  Laura E Rupprecht; Tracy T Smith; Rachel L Schassburger; Deanne M Buffalari; Alan F Sved; Eric C Donny
Journal:  Curr Top Behav Neurosci       Date:  2015

2.  Microinjections of acetaldehyde or salsolinol into the posterior ventral tegmental area increase dopamine release in the nucleus accumbens shell.

Authors:  Gerald A Deehan; Eric A Engleman; Zheng-Ming Ding; William J McBride; Zachary A Rodd
Journal:  Alcohol Clin Exp Res       Date:  2012-12-20       Impact factor: 3.455

3.  Abuse liability assessment of an e-cigarette refill liquid using intracranial self-stimulation and self-administration models in rats.

Authors:  M G LeSage; M Staley; P Muelken; J R Smethells; I Stepanov; R I Vogel; P R Pentel; A C Harris
Journal:  Drug Alcohol Depend       Date:  2016-09-01       Impact factor: 4.492

Review 4.  Putative role of brain acetaldehyde in ethanol addiction.

Authors:  Xin-sheng Deng; Richard A Deitrich
Journal:  Curr Drug Abuse Rev       Date:  2008-01

5.  Acetaldehyde involvement in ethanol's postabsortive effects during early ontogeny.

Authors:  Samanta M March; P Abate; Juan C Molina
Journal:  Front Behav Neurosci       Date:  2013-06-19       Impact factor: 3.558

6.  Acetaldehyde-reinforcing effects: a study on oral self-administration behavior.

Authors:  Alessandra T Peana; Giulia Muggironi; Marco Diana
Journal:  Front Psychiatry       Date:  2010-09-16       Impact factor: 4.157

7.  Naloxone's dose-dependent displacement of [11C]carfentanil and duration of receptor occupancy in the rat brain.

Authors:  Yeona Kang; Kelly A O'Conor; Andrew C Kelleher; Joseph Ramsey; Abolghasem Bakhoda; Seth M Eisenberg; Wenjing Zhao; Tyler Stodden; Torben D Pearson; Min Guo; Nina Brown; Jeih-San Liow; Joanna S Fowler; Sung Won Kim; Nora D Volkow
Journal:  Sci Rep       Date:  2022-04-19       Impact factor: 4.996

8.  Elucidating the biological basis for the reinforcing actions of alcohol in the mesolimbic dopamine system: the role of active metabolites of alcohol.

Authors:  Gerald A Deehan; Sheketha R Hauser; Jessica A Wilden; William A Truitt; Zachary A Rodd
Journal:  Front Behav Neurosci       Date:  2013-08-23       Impact factor: 3.558

9.  Behavioral and biochemical evidence of the role of acetaldehyde in the motivational effects of ethanol.

Authors:  Alessandra T Peana; Elio Acquas
Journal:  Front Behav Neurosci       Date:  2013-07-15       Impact factor: 3.558

10.  Involvement of the endogenous opioid system in the psychopharmacological actions of ethanol: the role of acetaldehyde.

Authors:  Laura Font; Miguel Á Luján; Raúl Pastor
Journal:  Front Behav Neurosci       Date:  2013-07-31       Impact factor: 3.558

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.